Allogene Therapeutics (ALLO) Insider Trading & Ownership $1.74 -0.07 (-3.61%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Allogene Therapeutics (NASDAQ:ALLO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage24.30%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$5.00 MNumber OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$158,167.09 Get ALLO Insider Trade Alerts Want to know when executives and insiders are buying or selling Allogene Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ALLO Insider Buying and Selling by Quarter Allogene Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/3/2025Earl Martin DouglasSVPSell6,404$1.71$10,950.84 2/3/2025Geoffrey M ParkerCFOSell4,361$1.73$7,544.53 2/3/2025Timothy L MooreInsiderSell14,746$1.71$25,215.66 1/21/2025Zachary RobertsEVPSell27,199$1.78$48,414.22 12/9/2024Deborah M MessemerDirectorSell9,136$2.18$19,916.48 12/5/2024Franz B HumerDirectorSell9,221$2.16$19,917.36 5/30/2024Franz B HumerDirectorSell11,200$2.34$26,208.00 5/16/2024Arie BelldegrunDirectorBuy1,724,137$2.90$4,999,997.30 (Data available from 1/1/2013 forward) ALLO Insider Trading Activity - Frequently Asked Questions Who is on Allogene Therapeutics's Insider Roster? The list of insiders at Allogene Therapeutics includes Alison Moore, Arie Belldegrun, David D Chang, Deborah M Messemer, Earl Martin Douglas, Eric Thomas Schmidt, Franz B Humer, Geoffrey M Parker, Owen N Witte, Rafael Amado, Stephen Mayo, Timothy L Moore, Veer Bhavnagri, and Zachary Roberts. Learn more on insiders at ALLO. What percentage of Allogene Therapeutics stock is owned by insiders? 24.30% of Allogene Therapeutics stock is owned by insiders. Learn more on ALLO's insider holdings. Which Allogene Therapeutics insiders have been buying company stock? The following insiders have purchased ALLO shares in the last 24 months: Arie Belldegrun ($4,999,997.30), and Geoffrey M Parker ($684.00). How much insider buying is happening at Allogene Therapeutics? Insiders have purchased a total of 1,724,327 ALLO shares in the last 24 months for a total of $5,000,681.30 bought. Which Allogene Therapeutics insiders have been selling company stock? The following insiders have sold ALLO shares in the last 24 months: Deborah M Messemer ($70,244.48), Earl Martin Douglas ($10,950.84), Franz B Humer ($46,125.36), Geoffrey M Parker ($7,544.53), Stephen Mayo ($42,900.00), Timothy L Moore ($25,215.66), and Zachary Roberts ($48,414.22). How much insider selling is happening at Allogene Therapeutics? Insiders have sold a total of 110,907 Allogene Therapeutics shares in the last 24 months for a total of $251,395.09 sold. Allogene Therapeutics Key ExecutivesDr. Arie S. Belldegrun F.A.C.S. (Age 75)M.D., Co-Founder & Executive Chairman Compensation: $649.1kDr. David D. Chang M.D. (Age 64)Ph.D., Co-Founder, President, CEO & Director Compensation: $994.6kMr. Joshua A. Kazam (Age 47)Co-Founder & Director Compensation: $260.5kMr. Timothy L. Moore Ph.D. (Age 63)Executive VP & Chief Technical Officer Compensation: $554.35k1 recent tradesDr. Zachary J. Roberts M.D. (Age 46)Ph.D., Executive VP of Research & Development and Chief Medical Officer Compensation: $747.39kMr. Geoffrey M. Parker (Age 59)Executive VP & CFO 1 recent tradesMs. Annie Yoshiyama (Age 40)Senior VP, Corporate Controller & Principal Accounting Officer Mr. Earl M. Douglas Esq. (Age 61)Senior VP, General Counsel, Compliance Officer & Corporate Secretary Ms. Susan R. Lundeen (Age 58)Chief People Officer Ms. Christine CassianoExecutive VP, Chief Corporate Affairs & Brand Strategy Officer More Insider Trading Tools from MarketBeat Related Companies Janux Therapeutics Insider Ownership Tarsus Pharmaceuticals Insider Ownership Vera Therapeutics Insider Ownership Iovance Biotherapeutics Insider Ownership Travere Therapeutics Insider Ownership Disc Medicine Insider Ownership NewAmsterdam Pharma Insider Ownership Wave Life Sciences Insider Ownership Schrödinger Insider Ownership Amphastar Pharmaceuticals Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:ALLO) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allogene Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
